Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line
- 1 December 2009
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (23), 6538-6543
- https://doi.org/10.1016/j.bmcl.2009.10.051
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Diagnosis and treatment of cutaneous melanoma: state of the art 2006*Melanoma Research, 2007
- Melanoma biology and new targeted therapyNature, 2007
- Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistanceExpert Review of Anticancer Therapy, 2007
- Choices in Adjuvant Therapy of MelanomaCancer Control, 2005
- Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid TumorsClinical Cancer Research, 2005
- Treatment of metastatic malignant melanomaCurrent Treatment Options in Oncology, 2005
- Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid TumorsJournal of Clinical Oncology, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989